News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
240,466 Results
Type
Article (11586)
Company Profile (28)
Press Release (228852)
Multimedia
Podcasts (10)
Webinars (3)
Section
Business (76299)
Career Advice (1064)
Deals (14504)
Drug Delivery (33)
Drug Development (35214)
Employer Resources (38)
FDA (6058)
Job Trends (5811)
News (129371)
Policy (9648)
Tag
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
2026 Genetown Elite (1)
Academia (760)
Academic (1)
Accelerated approval (2)
Adcomms (14)
Allergies (54)
Alliances (10334)
ALS (39)
Alzheimer's disease (599)
Antibody-drug conjugate (ADC) (65)
Approvals (6126)
Artificial intelligence (128)
Autoimmune disease (16)
Automation (9)
Bankruptcy (97)
Best Places to Work (5210)
BIOSECURE Act (2)
Biosimilars (59)
Biotechnology (22)
Bladder cancer (56)
Brain cancer (15)
Breast cancer (194)
Cancer (1397)
Cardiovascular disease (94)
Career advice (840)
Career pathing (9)
CAR-T (68)
Cell therapy (204)
Cervical cancer (17)
Clinical research (30390)
Collaboration (408)
Compensation (516)
Complete response letters (4)
COVID-19 (953)
CRISPR (18)
C-suite (86)
Cystic fibrosis (41)
Data (1400)
Depression (28)
Diabetes (152)
Diagnostics (2343)
Digital health (8)
Diversity, equity & inclusion (7)
Drug discovery (54)
Drug pricing (29)
Drug shortages (11)
Duchenne muscular dystrophy (51)
Earnings (55711)
Editorial (12)
Employer branding (5)
Employer resources (33)
Events (38493)
Executive appointments (341)
FDA (6738)
Featured Employer (11)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (387)
Gene editing (46)
Generative AI (9)
Gene therapy (154)
GLP-1 (372)
Government (1395)
Grass and pollen (3)
Guidances (39)
Healthcare (7347)
Huntington's disease (7)
IgA nephropathy (11)
Immunology and inflammation (77)
Indications (14)
Infectious disease (1020)
Inflammatory bowel disease (66)
Inflation Reduction Act (1)
Influenza (22)
Intellectual property (31)
Interviews (193)
IPO (9234)
IRA (13)
Job creations (969)
Job search strategy (743)
Kidney cancer (8)
Labor market (20)
Layoffs (160)
Leadership (5)
Legal (1723)
Liver cancer (40)
Lung cancer (217)
Lymphoma (106)
Machine learning (1)
Management (13)
Manufacturing (120)
MASH (44)
Medical device (5147)
Medtech (5147)
Mergers & acquisitions (5678)
Metabolic disorders (388)
Multiple sclerosis (47)
NASH (9)
Neurodegenerative disease (38)
Neuropsychiatric disorders (13)
Neuroscience (874)
NextGen: Class of 2025 (2243)
Non-profit (1475)
Northern California (1613)
Now hiring (8)
Obesity (197)
Opinion (67)
Ovarian cancer (38)
Pain (47)
Pancreatic cancer (40)
Parkinson's disease (79)
Partnered (5)
Patents (80)
Patient recruitment (54)
Peanut (33)
People (9564)
Pharmaceutical (11)
Pharmacy benefit managers (3)
Phase I (8295)
Phase II (13019)
Phase III (11539)
Pipeline (885)
Policy (33)
Postmarket research (1267)
Preclinical (2782)
Press Release (14)
Prostate cancer (66)
Psychedelics (18)
Radiopharmaceuticals (123)
Rare diseases (183)
Real estate (1151)
Recruiting (16)
Regulatory (7497)
Reports (21)
Research institute (728)
Resumes & cover letters (197)
Rett syndrome (4)
RNA editing (3)
RSV (30)
Schizophrenia (50)
Series A (58)
Series B (43)
Service/supplier (2)
Sickle cell disease (29)
Southern California (1363)
Special edition (8)
Spinal muscular atrophy (54)
Sponsored (11)
Startups (794)
State (1)
Stomach cancer (5)
Supply chain (44)
Tariffs (8)
The Weekly (10)
United States (12590)
Vaccines (328)
Venture capitalists (16)
Weight loss (126)
Women's health (5)
Worklife (4)
Date
Today (102)
Last 7 days (307)
Last 30 days (1531)
Last 365 days (19102)
2025 (6099)
2024 (18408)
2023 (17837)
2022 (21574)
2021 (22719)
2020 (20351)
2019 (17975)
2018 (12805)
2017 (12137)
2016 (10390)
2015 (12659)
2014 (9071)
2013 (6615)
2012 (7212)
2011 (7510)
2010 (6715)
Location
Africa (278)
Alabama (19)
Alaska (1)
Arizona (63)
Arkansas (6)
Asia (14527)
Australia (2233)
California (3622)
Canada (1007)
China (297)
Colorado (149)
Connecticut (165)
Delaware (109)
Europe (34081)
Florida (457)
Georgia (95)
Idaho (18)
Illinois (283)
India (11)
Indiana (151)
Iowa (6)
Japan (117)
Kansas (47)
Kentucky (9)
Louisiana (7)
Maine (32)
Maryland (434)
Massachusetts (2645)
Michigan (83)
Minnesota (177)
Mississippi (1)
Missouri (40)
Montana (15)
Nebraska (5)
Nevada (32)
New Hampshire (48)
New Jersey (985)
New Mexico (11)
New York (936)
North Carolina (424)
North Dakota (1)
Northern California (1613)
Ohio (95)
Oklahoma (4)
Oregon (14)
Pennsylvania (680)
Puerto Rico (3)
Rhode Island (12)
South America (429)
South Carolina (7)
Southern California (1363)
Tennessee (48)
Texas (512)
Utah (70)
Virginia (75)
Washington D.C. (28)
Washington State (335)
West Virginia (1)
Wisconsin (42)
240,466 Results for "4".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
In the Phase III MITIGATE trial, Uplizna cut IgG4-related disease flares by 87% versus placebo.
April 4, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
Roche acquired Spark Therapeutics in 2019 for $4.8 billion.
March 11, 2025
·
2 min read
·
Tristan Manalac
Job Trends
Bonus Episode: Q4 2024 Job Market Update
In this bonus episode,
BioSpace’s
vice president of marketing
Chantal Dresner
and careers editor
Angela Gabriel
take a look at Q4 job market performance and what we expect to see ahead.
January 21, 2025
·
1 min read
·
Angela Gabriel
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
1 min read
Press Releases
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
2 min read
Press Releases
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
1 min read
Press Releases
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
1 min read
Press Releases
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
1 min read
Press Releases
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
1 min read
1 of 24,047
Next
